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Non-human primates (NHP) provide a key component in the preclinical assessment pathway for new TB
vaccines. In the established models, Mycobacterium tuberculosis challenge is typically delivered to air-
ways of macaques either by aerosol or bronchoscopic instillation and therefore, an understanding of
these delivery routes would facilitate the comparison of data generated from models using different
challenge methods. This study compared the clinical effects, antigen-speciﬁc IFNg response proﬁles and
disease burden following delivery of comparable doses ofM. tuberculosis to the lungs of rhesus macaques
by either aerosol or bronchoscopic instillation. The outcome of infection in terms of clinical effects and
overall disease burden was comparable between both routes of challenge. However, the pathology in the
lungs differed as disease was localised to the site of inoculation following bronchoscopic instillation
while aerosol exposure resulted in lesions being evenly distributed through the lung. Whilst the IFNg
response to PPD was similar, responses to CFP10 and ESAT6 peptide pools measured with an ex vivo
ELISPOT differed with regards to responses to the N-terminal regions depending on the route of infec-
tion. Both challenge routes therefore provide valid and comparable models for evaluation of new TB
vaccines, although subtle differences in host responses may occur.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculosis (TB) continues to infect around 9 million people
annually and was responsible for almost 1.5 million deaths
worldwide in 2013 [1]. Although drug treatments are available and
effective against active disease, the regimens are long (around 6
months) and have unpleasant side effects, which lead to non-
compliance which in turn has contributed to the emergence of
multidrug resistant (MDR) and extremely drug resistant (XDR) TB.
There is a licensed vaccine available for TB; Bacille Calmette-Guerin
(BCG), but it has variable efﬁcacy depending on recipient age and
geographical location, but it is effective in preventing serious dis-
ease in children [2,3].ublic Health England, Porton
e).
Ltd. This is an open access article uThere is therefore an urgent need for novel vaccines and ther-
apeutics to prevent and control TB. One of the bottlenecks in the
development of new interventions against TB is the lack of any
identiﬁed correlates of protection, which means the only means of
testing efﬁcacy is by expensive, large scale clinical trials [4].
Therefore, preclinical animal models that can accurately predict
the effectiveness of vaccines in humans through challenge studies
are critical to identifying an improved TB vaccine. A range of
species including mice, guinea pigs, rabbits and non-human pri-
mates (NHP) are used to model human tuberculosis [5]. NHPs
provide the most relevant model of tuberculosis due to their
similarity to humans [6e8], and reviews of published studies using
the TB NHP model reveal that the selection of model parameters,
including the macaque species, challenge route and size of the
challenge dose, can affect the outcome of experimental TB expo-
sure in NHPs [6e8]. The importance of route of Mycobacterium
tuberculosis administration can be observed clearly in the murinender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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infection by the aerosol route than by intravenous administration
[9].
M. tuberculosis challenge is typically delivered to airways of
macaques either by aerosol, intratracheal, intranasal or broncho-
scopic instillation [8]. Aerosol exposure and bronchoscopic instil-
lation cause granulomatous disease and anM. tuberculosis antigen-
speciﬁc IFNg response, both of which are characteristic features of
TB disease [10,11]. Differences in pulmonary disease distribution
have been reported as, following bronchoscopic instillation, disease
is primarily localised to the site of inoculation in the lung, whereas
aerosol exposure results in disease evenly distributed throughout
the lung [12,13], as well as potential differences observed in rates of
disease progression and dissemination to extra-pulmonary tissues.
The immune response is important to assess in vaccine evalu-
ation studies in animal models to attempt to predict efﬁcacy and
immunogenicity. In humans, the immune response to TB is char-
acterised by activation of Th1 T-cells and production of proin-
ﬂammatory cytokines including IFNg, TNFa, and IL-2 [14,15]. IFNg
production in response to CFP10 and ESAT6 as measured using an
ex vivo ELISPOT assay is detected in naturally infected humans [16]
as well as primates after aerosol and bronchoscopic instillation
[10,11].
In order to provide the most clinically relevant and reﬁned
models for assessment of new TB therapeutics, it is important to
determine the impact of challenge route on infection outcome,
including the immune response. To date, a comparison of chal-
lenge routes in the same macaque species with the same
M. tuberculosis strain and challenge dose has not been reported.
The present study was set up to characterise the outcome of
infection with an equivalent dose of M. tuberculosis delivered to
rhesus macaques either by aerosol exposure or bronchoscopic
instillation. In addition, the immune response proﬁles induced and
the severity of the resulting disease between the two routes were
compared in order to determine the impact that challenge route
may have in future vaccine evaluation studies using macaque
models.2. Materials and methods
2.1. Experimental animals
Four male rhesus macaque of Indian genotype, aged 3e4 years
were obtained from an established UK breeding colony for this
study. Absence of previous exposure to mycobacterial antigens was
conﬁrmed by screening using an ex vivo IFN-g ELISPOT (MabTech,
Nacka. Sweden) to measure responses to PPD (SSI, Copenhagen,
Denmark), and pooled 15-mer peptides of ESAT6 and CFP10 (Pep-
tide Protein Research LTD, Fareham, U.K.).
Animals were housed in compatible social groups, in accordance
with the Home Ofﬁce (UK) Code of Practice for the housing and
Care of Animals Bred, Supplied or Used for Scientiﬁc Purposes,
December 2014, and the National Committee for Reﬁnement,
Reduction and Replacement (NC3Rs), Guidelines on Primate Ac-
commodation, Care and Use, August 2006 (NC3Rs, 2006). Animals
were sedated by intramuscular (IM) injection with ketamine hy-
drochloride (Ketaset, 100 mg/ml, Fort Dodge Animal Health Ltd,
Southampton, UK; 10 mg/kg) for procedures requiring removal
from their housing. None of the animals had been used previously
for experimental procedures. All animal procedures were approved
by the Public Health England Ethical Review Committee, Porton
Down, UK, and authorized under an appropriate UK Home Ofﬁce
project license.2.2. Clinical procedures
Animals were monitored daily for behavioural and clinical
changes. Behaviour was evaluated for contra-indicators including
depression, withdrawal from the group, aggression, changes in
feeding patterns, respiration rate and coughing. Prior to blood
sample collection, aerosol challenge and euthanasia, animals were
weighed, body temperature measured and examined for gross
abnormalities. Red blood cell (RBC) haemoglobin levels were
measured using a HaemaCue haemoglobinometer (Haemacue Ltd,
Dronﬁeld, UK) to identify the presence of anaemia, and erythrocyte
sedimentation rates (ESR) were measured using the Sediplast sys-
tem (Guest Medical, Edenbridge, UK) to detect and monitor
inﬂammation induced by infection with M. tuberculosis.
The time of necropsy, if prior to the end of the planned study
period, was determined by experienced primatology staff and
based on a combination of the following adverse indicators:
depressed or withdrawn behaviour, abnormal respiration (dysp-
noea), loss of 20% of peak postechallenge weight, ESR levels
elevated above normal (>20mm), haemoglobin level below normal
limits (<100 g/dL), increased temperature (>41 C) and abnormal
chest X-ray or computed tomography scan.
2.3. M. tuberculosis challenge strain
The bacterial suspension used for challenge was prepared from
stocks of the M. tuberculosis Erdman strain K 01 (BEI Resources). A
stock suspensionwas initially prepared from a 5ml bacterial starter
culture originally generated from colonies grown on Middlebrook
7H11 supplemented with oleic acid, albumin, dextrose and catalase
(OADC) selective agar (BioMerieux, UK). A liquid batch culture was
then grown to logarithmic growth phase in 7H9 medium (Sigma-
eAldrich, UK) supplemented with 0.05% (v/v) Tween80 (Sigma-
eAldrich, UK). Aliquots were stored at80 C. The titre of the stock
suspension was determined from thawed aliquots by enumeration
of colony forming units cultured onto Middlebrook 7H11 OADC
selective agar. The stock of Erdmanwas stored at a concentration of
1.1  108 CFU/ml.
2.4. Aerosol exposure
The methodology and apparatus used to deliver M. tuberculosis
via the aerosol route was as previously described [11]. In brief,
mono-dispersed bacteria in particles were generated using a 3-jet
Collison nebuliser (BGI) and, in conjunction with a modiﬁed Hen-
derson apparatus [17], delivered to the nares of each sedated pri-
mate via a modiﬁed veterinary anaesthesia mask. Challenge was
performed on sedated animals placed within a ‘head-out’, pleth-
ysmography chamber (Buxco, Wilmington, North Carolina, USA) to
enable the aerosol to be delivered simultaneously with the mea-
surement of respired volume. The aerosol delivery process was
designed to result in the deposition of a target dose of 35 CFU in the
lungs. The number of bacilli deposited and retained in the lungs of
macaques cannot be measured directly and the quantiﬁcation of
the dose must be calculated from the concentration of viable or-
ganisms in the aerosol (Caero) and the volume of aerosol inhaled by
the animal. This ‘presented dose’ (PD) is the number of organisms
that the animals inhale. Caero is either measured directly using air
sampling within the system or may be calculated using the con-
centration of organisms in the nebulizer (Cneb) and a ‘spray factor’
which is a constant derived from data generated for the speciﬁc
organism with identical aerosol exposure parameters. The calcu-
lations to derive the PD and the retained dose (the number of or-
ganisms assumed to be retained in the lung) have been described
previously for high/medium aerosol doses [11,18,19]. The assumed
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factor. Retention factors for rhesus macaques are described by
Harper and Moreton [20] but a reﬁnement of the retention factor
for M. tuberculosis infections has been derived from cumulative
data relating the PD to the number of lesions that have developed
three weeks after challenge measured by CT.2.5. Bronchoscopic instillation
The bacterial inoculum for intrabronchial delivery was prepared
by dilution of an aliquot from the same suspension used for aerosol
challenge into sterile PBS that provided a suspensionwhereby 2 ml
contained approximately 35 CFU, which was veriﬁed by retro-
spective analysis. Each subject was anaesthetised with an intra-
muscular injection of a combination of ketamine hydrochloride
(10 mg/kg. Anesketin, Eurovet Clinical Health, Bladel, The
Netherlands), and medetomidine hydrochloride (50 ug/kg Sedator,
Eurovet Clinical Health, Bladel, The Netherlands), and placed in
ventral recumbency. The vocal chords were visualised using a
laryngoscope and were sprayed with 2% w/v lignocaine hydro-
chloride (Intubeaze, Dechra Veterinary Products, Shrewsbury, UK)
prior to insertion of a pre-sterilised bronchoscope (Allscope XE30
4-mm ﬂexible bronchoscope; VES, Essex, UK). After insertion into
the trachea, the bronchoscope was manoeuvred through the right
bronchus into the right lower lung lobe and 2 ml of bacterial sus-
pensionwas injected. Full distribution of the inoculumwas ensured
by subsequent delivery of 2 ml sterile saline, followed by 5 ml air.2.6. Computed tomography (CT) imaging
CT scans were collected from animals using a 16 slice Lightspeed
CT scanner (General Electric Healthcare, Milwaukee, WI, USA) as
described previously [19,21]. In order to enhance visualisation of
lesions and lymph nodes, Niopam 300 (Bracco, Milan, Italy), a non-
ionic, iodinated contrast medium, was administered intravenously
(IV) at 2 ml/kg body weight. Scans were evaluated for the number
and distribution of pulmonary lesions across lung lobes and the
presence of characteristic features of TB disease, for example:
nodule cavitation, conglomeration and consolidation as an indica-
tor of alveolar pneumonia and a ‘tree-inebud’ pattern as an indi-
cator of bronchocentric pneumonia. The lung-associated lymph
nodes were assessed for enlargement and the presence of necrosis.2.7. Immunological analysis
An ELISPOT assay was applied to measure the frequency of
M. tuberculosis antigen-speciﬁc IFNg producing cells in PBMC using
an NHP cross-reactive human IFNg kit (Mabtech, Sweden) accord-
ing to the manufacturer's instructions. PBMC were isolated using
FicollePaque Plus (GE Healthcare, UK) using standard procedures.
2  105 and 1  105 PBMC were incubated with either medium
(RPMI supplemented with Hepes buffer, Penicillin/Streptomycin, L-
glutamine, 2-mercaptoethanol (all SigmaeAldrich, UK) and 5%
foetal calf serum (FCS, Labtech)), PPD (10 mg/ml) (Statens Serum
Institute, Denmark) or peptide pools of CFP10 or ESAT6 at 37 C 5%
CO2 overnight. Peptide pools were comprised of overlapping 15
mer peptides from peptidesynthetics (UK) used at a concentration
of 50 mg/ml for each CFP10 and ESAT6 pool. Plates were analysed
using a CTL Immunospot S6 reader and software (Bonn, Germany).
Spot forming units (SFU) per million cells were calculated from the
antigen stimulated wells minus the media only wells. Area under
the curve (AUC) was calculated using GraphPad Prism software (v6)
for Windows (La Jolla California, USA).2.8. Necropsy
Animals were anaesthetised and clinical data collected. Blood
samples were taken prior to euthanasia by intra-cardiac injection of
a lethal dose of anaesthetic (Dolelethal, Vetoquinol UK Ltd, 140 mg/
kg). A post-mortem examination was performed immediately and
gross pathological changes were scored using an established sys-
tem based on the number and extent of lesions present in the lungs,
spleen, liver, kidney and lymph nodes; described previously [10].
2.9. Histopathological examination
Representative samples from each lung lobe (seven per animal)
and other organs, were processed to parafﬁn wax, sectioned at
3e5 mm and stained with haematoxylin and eosin (HE). For each
lung lobe, tissue slices containing obvious lesions were chosen for
histological examination. Where gross lesions were not visible, a
sample was taken from a pre-deﬁned anatomical location from
each lobe to establish consistency between animals. Sections of
lung-associated lymph nodes (trachea-bronchial at the bifurcation
and cranial and caudal to the bifurcation) and other tissues were
evaluated for the presence of tuberculous lesions. Lesions in the
lung parenchyma were identiﬁed, categorised and counted as
described previously [19]. Brieﬂy, lesions deﬁned as “unorganised”
(Types 1e3) were those lacking a peripheral cuff of lymphocytes,
while “organised” lesions were those with a cuff of lymphocytes
(Types 4 and 5). Classic largely well demarcated granulomas with
central, caseous necrosis and a variable rim of lymphocytes, were
classiﬁed as Type 6 lesions in line with studies by Kaushel et al. [6],
and Lin et al., [10]. In one HE stained section from each lung lobe,
granulomas types, as described above were counted and recorded.
Further features included coalescing lesions, cavity formation and
fulminating pneumonia, the latter deﬁned as representing inﬂam-
matory changes within the parenchyma, extending between
granulomas were recorded, together with additional, morpholog-
ical features: airway invasion, lymphatic inﬂammation/involve-
ment, arterial wall inﬁltration by inﬂammatory cells and
granulomas in bronchovascular, connective tissue.
2.10. Bacteriology
The spleen, kidneys, liver and tracheobronchial lymph nodes
were sampled for the presence of viable M. tuberculosis post-
mortem as described previously [10]. Weighed tissue samples
were homogenized in 2 ml of sterile water, then either serially
diluted in sterile water prior to being plated, or plated directly onto
Middlebrook 7H11 OADC selective agar. Plates were incubated for
3 weeks at 37 C and resultant colonies were conﬁrmed as
M. tuberculosis and counted.
3. Results
3.1. Delivery of equivalent doses of M. tuberculosis by aerosol or
bronchoscope
Doses of M. tuberculosis delivered by aerosol were of similar
magnitude to those delivered by bronchoscope. The culture of
samples collected during aerosol delivery conﬁrmed that the two
macaques were exposed to presented doses of 115 CFU (U45) or
122 CFU (U75), respectively, which were calculated to result in
estimated doses of 29 CFU (U45) or 31 CFU (U75) retained in the
lungs. Similarly culture of samples collected during the preparation
of the suspension delivered by bronchoscopy quantiﬁed the dose
delivered to the lungs at 29 CFU.
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The disease progressionwas similar between theM. tuberculosis
challenge routes (Figure 1A). Following exposure toM. tuberculosis,
the macaques were monitored daily for changes in behaviour and
every two weeks for changes in clinical parameters for 20 weeks
after challenge. All four animals showed changes in behaviour and
clinical parameters consistent with tuberculosis infection,
including weight loss (Figure 1B), increased ESR (Figure 1) and
reduction in red blood cell haemoglobin level (Figure 1D). Cough
was observed and respiration rates were seen to become more
rapid. Disease progressed to a level that met the humane endpoint
criteria in one animal that received challenge by the aerosol route
(U75, peak post challenge body weight loss: 17%, ESR: 42 mm, RBC
[Hb]: 96 g/dL) at week 10, and one animal that was challenged by
bronchoscopic instillation (U9, peak post challenge body weight
loss: 20.8%, ESR: 79 mm, RBC[Hb]: 97 g/dL). At the end of the
planned 20 week study period (Figure 1D), both the remaining
animals were euthanized. The clinical parameters measured on the
day of euthanasia of the animal that was challenged by broncho-
scopic instillation (U64) reached endpoint criteria (peak post
challenge bodyweight loss: 24.9%, ESR: 25mm, RBC[Hb]: 105 g/dL),
while those measured in the animal that received challenge by the
aerosol route (U45) remained within the normal ranges for the
species (peak post challenge body weight loss: 2.1%, ESR: 1 mm,
RBC[Hb]: 126 g/dL).
3.3. CT evaluation of pulmonary disease
The CT scans collected at three and eight weeks after exposure
to M. tuberculosis revealed differences in the pattern of pulmonary
disease that were characteristic for the route of administration
(Table 1). Aerosol exposure led to the development of discrete
nodules in multiple lobes in both animals (U45, U75), and the
number of nodules increased between three (30 and 43) and eight
(37 and 71) weeks after challenge (Figure 2A and B). One aerosol-Figure 1. Clinical proﬁles from rhesus macaques infected withM. tuberculosis either by the a
closed symbols; aerosol. A) Survival plot, B) Total body weight, C) Erythrocyte sedimentatiexposed animal (U75) showed evidence of pneumonia with areas
of consolidation present in the right and left lower lobes three
weeks after challenge, and both aerosol-exposed animals possessed
consolidated areas in all lobes by eight weeks. Furthermore, eight
weeks after challenge, U75 had also developed a cavity in the right
upper lobe, and the middle lobe had become partially necrotic.
Three weeks after intrabronchial inoculation, discrete nodules (10
and 5) were only seen in the right lower lobe in both animals (U9,
U64) (Figure 2C) and by week eight it was no longer possible to
identify discrete nodules in the lung (Figure 2D). Consolidationwas
only detected in the right lower lobe in both animals three weeks
after bronchoscopic inoculation, and this had become extensive by
eight weeks. Scans from both animals at week eight showed the
radiological feature of ground glass opaciﬁcation in the middle
lobe, caused by the thickening of alveolar walls, or the presence of
cells or ﬂuid ﬁlling the alveolar spaces which can represent active
disease, such as pulmonary oedema, pneumonia, or diffuse alveolar
damage. Additionally, one animal (U9) had developed a cavity in
the right lower lobe and the other (U64) showed evidence of ne-
crosis in the same lobe, as well as collapse of the left lower lobe due
to compression of the lower lobe bronchus by enlarged lymph
nodes.
Enlarged tracheobronchial lymph nodes were detected in one
(U75) of the two aerosol-exposed animals and both of the intra-
bronchially inoculated animals at both three and eight weeks after
challenge. Evidence of necrosis was seen in subcarinal lymph nodes
of the intrabronchially inoculated animal U9 at week three, and in
both the intrabronchially inoculated animals and the aerosol-
exposed animal, U75, at week eight after challenge. The right
supraclavicular fossa lymph nodes appeared enlarged and necrotic
in both the animals that received intrabronchial inoculation when
analysed eight weeks after challenge, but were not detected in the
scans from either of the aerosol-exposed animals. Splenic abscesses
were reported in U9 eight weeks after intrabronchial inoculation.
Extra-pulmonary disease was not identiﬁed from the CT scans of
the other three animals.erosol route or by bronchoscopic instillation. Open symbols; bronchoscopic instillation,
on rate (ESR), D) Haemoglobin level.
Table 1
Summary of CT ﬁndings.
Aerosol Bronchoscopic instillation
Lung
Discrete pulmonary
nodules
Evenly distributed through lobes
Number of discrete lesions increased over time
Restricted to lower right lobe at week 3
Not countable as individual lesions due to consolidation/conglomeration by week 8
Pneumonia Areas of consolidation in all lung lobes andweeks
3 and 6
Consolidation in the lower right lobe of both animals at week 3 and 8
Ground glass opaciﬁcation in middle right lobe of both animals at week 8 e evidence of intra-
bronchial spread?
Cavitation One animal, right upper lobe One animal, right lower lobe
Other features One animal left lower lobe collapse due to lymph node compression
Tracheobronchial LN
Enlargement LNs seen in one animal at week 3 and 8 LNs seen in both at weeks 3 and 8
Right Supraclavicular fossa node enlargement in both
Necrotic sub-carinal LN Neither at week 3, but 1 at week 8 One at week 3 and both at week 8
Extra-pulmonary
disease
Neither One animal displayed splenic abscesses
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Disease burden was evaluated during a post-mortem examina-
tion conducted at the point at which disease progressed to a level
that met the humane endpoint criteria in three animals at weeks 10
(U75), 12 (U9) and 20 (U64) after challenge, and at the end of the
planned study period (week 20) for the remaining animal (U45).
The total gross pathology scores obtained from the pair of aerosol-
exposed animals (55, 81) were equivalent to the scores from the
pair of intrabronchially-challenged animals (60, 81) (Figure 3A).
Closer evaluation of the break-down of the total score revealed
subtle differences between the disease resulting from the two de-
livery routes (Figure 3B and C). The scores from the left lung lobesFigure 2. CT in vivo images of lungs of rhesus macaques infected with M. tuberculosis by e
difference in number and distribution of focal areas of infection, arrowed, secondary to the
week 3, B) Representative aerosol infected animal, week 8, C) Representative bronchoscopic i
week 8.were larger in the aerosol-exposed animals (lower lobe scores,
aerosol group: 5 and 8, intrabronchial group: 3 and 4; upper lobe
score, aerosol group 7 and 9, intrabronchial group: 4 and 4); by
contrast, the intrabronchially challenged animals showed a larger
disease score associated with the paratracheal lymph nodes
(Intrabronchial group scores: 2 and 6; Aerosol group scores: 0 and
1).
Following necropsy, MR images of the lungs of each animal were
collected [11,19,23]. Images from each sequential tissue slice were
reconstructed into three-dimensional images of the entire lung
using computer software for all study subjects. Representative
images from animals that were exposed by the two different routes
to M. tuberculosis are shown in Figure 3D and E. The lesions wereither aerosol exposure or bronchoscopic instillation. The CT images demonstrate the
different techniques of administration of TB. A) Representative aerosol infected animal,
nstillation infection at week 3, D) Representative bronchoscopic instillation infection at
Figure 3. Disease burden pathology readouts from rhesus macaques infected with M. tuberculosis either by the aerosol route or by bronchoscopic instillation. A) Total pathology
scores, B) breakdown of pathology score for each tissue, C) diagrams illustrating the pathology scores for the lungs, spleen, liver and kidneys after bronchoscopic instillation or
aerosol dosing. Greyscale indicates number and size of lesions. Panels D and E represent ex vivo MRI images of the lungs. D) Aerosol infected E) bronchoscopic instillation. The
volumetric MRI shows the widespread multi lobar infection following aerosol administration (D) compared to the almost unilobar distribution following intrabronchial admin-
istration (E). F. Bacterial burden in extra-pulmonary tissues and hilar lymph nodes, * below limit of detection (1.95 log10 CFU/g) in one animal.
L. Sibley et al. / Tuberculosis 96 (2016) 141e149146evenly distributed throughout all of the lobes of the lung following
aerosol exposure (Figure 3D), while intrabronchial placement led to
a more focal disease on the right side of the lung with an increased
level of endobronchial involvement (Figure 3E). The disease at the
site of intrabronchial inoculation appeared to be more severe
compared to the level in any of the lung lobes after aerosol
exposure.Evaluation of the microscopic pathology of the lung did not
detect obvious microscopic differences between animals and
groups. Microscopic lesions attributable to (or consistent with)
infection with M. tuberculosis (Mtb) were observed in all the lung
lobes in all animals in both groups. Granulomas classiﬁed as Types
5 and 6, were the most prevalent, many of which were coalescing.
Granulomas of Types 1 to 4 were observed at variable levels
L. Sibley et al. / Tuberculosis 96 (2016) 141e149 147between lung lobes and between animals. Cavity lesions were seen
in two animals [U9 (intra-bronchial) and U45 (aerosol)]. Airway
involvement was observed in all animals, being most prominent in
animals U9 (intra-bronchial) and U45 (aerosol). However, with
respect to airway invasion, it was recognised that in three animals,
U45 and U75 (aerosol challenge) and U9 (intra-bronchial chal-
lenge), the right and left sides of the lung were equally affected. In
animal U64, airway invasion was only seen in the right middle and
lower lung lobes. In addition, perivascular, lymphoid cufﬁng;
lymphatic inﬂammation/involvement; vascular (mainly arterial)
wall inﬁltration by inﬂammatory cells were occasionally recorded,
and giant cells, sometimes bizarre, were frequently seen. In all
animals, tracheobronchial lymph nodes were enlarged and largely
replaced by granulomatous lesions with caseous necrosis and oc-
casional calciﬁcation. Microscopic granulomas were detected in
tracheobronchial lymph nodes of all animals. In the two animals in
the intra-bronchial challenge group, tuberculous lesions were
detected in lymph nodes distant from the lungs, U64 (right axillary
lymph node) and U9 (right inguinal, hepatic and thoracic lymph
nodes). In the aerosol challenge group, lesions were not observed in
the lymph nodes other than the pulmonary nodes. A range of
tuberculous granulomas from small granulomatous lesions to large,
caseating lesions were observed in the livers of all four animals and,
similarly, granulomatous lesions of variable size were seen in both
left and right kidneys of all four animals. Examination of the spleen
revealed typical, caseous, tubercular lesions in three animals [U9,
U64 (intra-bronchial challenge) and U75 (aerosol challenge)] but
lesions were not observed in animal U45. In two animals, U9 (intra-
bronchial challenge) and U75 (aerosol challenge), parietal pleural
involvement (thoracic cavity) with tuberculous lesions was seen.
3.5. Extra-pulmonary organ-speciﬁc bacterial burden
The bacterial burden was evaluated in the liver, spleen, kidneys,
hilar lymph nodes, blood and urine for all animals. M. tuberculosis
was isolated from the spleen, kidneys, and liver from all four ani-
mals and the hilar lymph nodes from both of the aerosol challenged
animals (U45, U75) and one of the intrabronchially challenged
animals (U9). The mean values (CFU/g) for each route of infection
across each of the tissue types are shown in Figure 3F and the value
for each of the pair of animals is indicated by the range bars. No
bacteria were recovered from the hilar lymph node of animal U64
but only a small tissue sample (0.11 g) was available for assessment.
For this animal the value given is 0.5 the limit of detection (1.95
log10 CFU/g). A similar level of bacterial burden was seen between
the animals and between the delivery routes, indicating a similar
distribution of extra-pulmonary dissemination with both routes of
infection.M. tuberculosiswas not cultured at detectable levels from
the blood or urine from any of the four animals.
3.6. Immunological analysis
An ex vivo ELISPOT assay was used to measure the
M. tuberculosis-speciﬁc IFNg response at two weekly intervals over
20 weeks following challenge (Figure 4) by assessing responses to
the TB antigens PPD and overlapping 15 mer peptides of CFP10 and
ESAT6 arranged into three pools (A, B and C). All animals, irre-
spective of challenge route, made a high PPD-speciﬁc response to
infection with similar kinetics (Figure 4A). High responses were
also seen to CFP10 and ESAT6 summed peptide pools (Figure 4B and
C). Area under the curve (AUC) analysis of the CFP10 response
measured as sum of SFU to peptide pools A, B, and C suggested a
trend for higher responses in the intrabronchially challenged ani-
mals (Figure 4J). Similar examination of the responses made to the
individual peptide pools revealed CFP10 peptide pool A stimulateda response in the macaques which received M. tuberculosis by
bronchoscope that was ﬁve times greater than the mean response
observed in the macaques exposed by aerosol (Figure 4K). The
opposite trend was observed with CFP10 peptide pool B, where the
aerosol challenged animals showed a higher response to the pep-
tide pool (Figure 4K). The responses to CFP10 pool C were not
markedly different between the two challenge routes (Figure 4K). A
high, early response to ESAT6 predominantly against peptide pool A
was seen in the aerosol exposed animals that was not seen in the
animals that received M. tuberculosis by bronchoscope (Figure 4G).
For ESAT6 peptide pools B, the initial kinetics were similar between
challenge routes (Figure 4H) but the overall AUC analysis showed
that the response was higher in the bronchoscopic instillation
group (Figure 4L), which can be attributed to a longer lasting
response in this group. In ESAT6 peptide pool C, the challenge
routes showed similar responses between challenge routes
(Figure 4I and L).
4. Discussion
Although aerosol is the natural route of TB transmission, many
vaccine efﬁcacy evaluations are performed in macaque models that
use the bronchial route for challenge because of technical expedi-
ency. Speculation exists as to whether the outcome is equivalent
when either delivery route for challenge is used, and to date there
have been no head-to-head comparisons. The aim of this study was
to evaluate the outcome of M. tuberculosis infection in rhesus ma-
caques following delivery of equivalent doses to the lung by aerosol
or by bronchoscopy. As NHP models provide a key component in
the preclinical assessment pathway for new TB vaccines, and will
become increasingly important as a gateway to clinical trials [22],
an understanding of the impact of using intra-bronchial or aerosol
delivery needs to be determined to enable the comparison of data
generated from models using different challenge routes.
The challenge doses of M. tuberculosis delivered for this study
were comparable in terms of the estimated retained dose. The small
variation in the calculated doses is a reﬂection of the technical
challenges associated with delivery, the calculation of the dose
delivered and the estimation of the dose retained. Delivery of
M. tuberculosis by aerosol or bronchoscope induced equivalent
clinical outcomes, PPD-speciﬁc IFNg response proﬁles, and overall
disease burden including extra-pulmonary bacterial load and his-
tological changes. Changes in clinical parameters, such as body
weight, extra-pulmonary spread and gross pathology assessment
scores are important measures of disease burden, that when
compared between test and control groups in vaccine evaluation
studies provide key indicators of protective efﬁcacy. The indications
from this study suggest that the outcome of vaccine evaluation
assessments based on these readouts, using either route of
M. tuberculosis delivery, would be equally capable of revealing new
vaccines with good protective potential. Candidate vaccines would
not be disadvantaged by the method of challenge delivery used in
the NHP model selected for the assessment. Further work using a
larger group of animals will be required to conﬁrm the compara-
bility of these readouts between intrabronchial and aerosol de-
livery models and their utility as cross model comparators.
Although the effect on the host resulting from the two delivery
routes appeared to be equivalent, differences were seen in the
distribution of pulmonary disease induced following aerosol or
bronchoscopic delivery; these differences were in line with those
previously reported [12,13,23,24]. The disease which developed
following inoculation by bronchoscope showed increased severity
on the right side of the lung with changes being most severe in the
right lower lobes, while aerosol exposure resulted in disease spread
evenly through both sides of the lung. The targeted bronchoscopic
Figure 4. IFNg ELISPOT responses to stimulation with PPD or CFP10 and ESAT6 peptide pools after aerosol or bronchoscopic instillation challenge withM. tuberculosis. IFNg ELISPOT
PBMC responses to stimulation over time from rhesus macaques challenged withM. tuberculosis by either bronchoscopic instillation (open symbols) or by aerosol (closed symbols).
Dotted line indicates time of challenge with M. tuberculosis. A) Responses to PPD, B) responses to summed peptide pools of CFP10, C) responses to summed peptide pools of ESAT6.
Panels DeI: IFNg ELISPOT PBMC responses to stimulation with peptides pools over time D) CFP10 peptide pool A, E) CFP10 peptide pool B, F) CFP10 peptide pool C, G) ESAT6 peptide
pool A, H) ESAT6 peptide pool B, I) ESAT6 peptide pool C. Panels JeL area under the curve analysis J) PPD and summed peptide pools of CFP10 and ESAT6, K) CFP10 summed peptide
pools, L) ESAT6 summed peptide pools.
L. Sibley et al. / Tuberculosis 96 (2016) 141e149148delivery and uneven spread of disease in the lung resulted in areas
that showed either increased, equivalent or reduced levels of dis-
ease compared to that induced by aerosol delivery. In human TB
infection, disease is heterogeneous among the population; disease
in the lung can be one sided, or distributed throughout the tissue
[25]. Therefore, despite the observed differences in lung pathology,
both routes used for experimental infection gave rise to features
that were characteristic of TB-induced disease human infection.
Furthermore, the route of delivery did not inﬂuence the micro-
scopic nature of the granulomas that developed in the lungs.
Tuberculous lesions were identiﬁed in non-pulmonary lymph
nodes of the animals that received intra-bronchial challenge, but
were not observed in the equivalent lymph in the aerosol challenge
group which may be suggestive of a more rapid dissemination and
involvement of the lymph nodes although the small size of this
studymeans ﬁrm conclusions cannot be drawn from these ﬁndings.The variation in pulmonary disease arising from the two routes
of delivery, however, may induce differences in the host response.
In this studywe used an ex vivo ELISPOTassay to evaluate the ESAT6
and CFP10-speciﬁc IFNg responses to infection and, although ani-
mal numbers are small, some consistent differences were seen in
the responses made by aerosol- or intrabronchially-challenged
animals. The consistency of the responses made by each pair of
animals that received M. tuberculosis by the same route, and the
difference in the responses between groups of outbred NHPs, is
noteworthy. The ESAT6 and CFP10 proﬁles observed in the group
infected following aerosol exposure are similar to those reported in
naturally-infected humans, which generally show immune re-
sponses to motifs found in the ESAT6 N-terminus and C-terminus
(ESAT6 pools A, B and C) and CFP10 middle and C-terminus (CFP10
pools B and C) [16,26,27]. However the macaques infected by
bronchoscopic instillation made an IFNg response to CFP10 peptide
L. Sibley et al. / Tuberculosis 96 (2016) 141e149 149pool A, which corresponds to the CFP10 N-terminal region, which
was shown by Arlehamn et al. to be only weakly immunogenic in
humans [16]. Further studies using larger group sizes would be
necessary to conﬁrm these observations and evaluate the
implications.
This study indicates that the delivery of comparable doses of
M. tuberculosis to the lungs of rhesus macaques by either aerosol or
bronchoscopy results in comparable outcomes. Therefore, both
challenge routes for experimental infection of macaques provide
valid models for evaluation of new TB vaccines. There may be some
implications in terms of immune response to antigens that is a
consequence of route of challenge, but further work is required to
verify any differences.
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